Apollo Endosurgery, Inc. announced that the company expects full year 2022 revenue between $73 million and $75 million, representing growth of approximately 16% to 19% over 2021. The Company continues to monitor the potential and uncertain impact of the ongoing COVID-19 pandemic. Should hospitals or outpatient centers, where the company's procedures are performed, experience continued or additional surges in cases, and need to defer elective procedures to preserve capacity for COVID-19 patients, the company's ability to achieve these financial projections could be adversely affected.
Apollo Endosurgery, Inc.
Equities
APEN
US03767D1081
Medical Equipment, Supplies & Distribution
1st Jan change | Capi. | |
---|---|---|
+75.72% | 1.26TCr | |
-24.76% | 741.73Cr | |
+10.75% | 673.81Cr | |
+11.63% | 533.52Cr | |
-15.51% | 478.33Cr | |
+29.47% | 461.75Cr | |
-24.82% | 368.61Cr | |
-22.03% | 290.23Cr | |
+51.44% | 236.85Cr |